Other
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement
Sentiment Analysis
Bullish0.80
BEARISHNEUTRALBULLISH
Corvus Pharmaceuticals maintains a “Strong Buy” rating, driven by advancing soquelitinib in relapsed/refractory PTCL and moderate-to-severe atopic dermatitis [AD]. The company anticipates a pivotal interim futility analysis for its phase 3 PTCL trial in Q1 2027, representing a major inflection point.
Positive phase 1 AD data and the initiation of the phase 2 SIERRA1 study, with topline results expected in Q3 2027, reinforce the pipeline’s potential.
With $215.2M in cash, the company is funded into Q2 2028, minimizing near-term dilution risk and supporting ongoing clinical development.
Sponsored
Source: Seeking Alpha
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。